Sinovac Biotech Ltd. (Sinovac) announced that it has commenced Phase I human clinical trials of its SARS vaccine.

The first subjects were injected with the vaccine on the 22nd of May 2004 at the Sino-Japan Friendship Hospital in Beijing. More details will follow in a follow-up Sinovac news release on 24th May 2004. Sinovac specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and SARS.